StockData
RVPHOTCPharmaceutical PreparationsFiscal year ends December 31

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.45−0.02 (-4.36%)

Close on Oct 19, 2026

Market cap
$5.94M
P/E (TTM)
–
Dividend yield
–

REVIVA PHARMACEUTICALS HOLDINGS, INC. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-420.0%

Financial strength

Current ratio
3.56
Debt to equity
–
Debt to assets
–
Cash to current liabilities
335.2%

Valuation

P/E ratio
–
Price to sales
–
Price to book
0.39
Dividend yield
–